Shulou(Shulou.com)11/24 Report--

Thanks to CTOnews.com netizens, assassins for their clues delivery! CTOnews.com, November 14 (Xinhua)-- artificial intelligence is helping the world find new drug treatments, and one of the leading companies is about to usher in an important milestone as it enters a late-stage trial of drugs discovered by algorithms. The company, Insilico Medicine, which is based in Hong Kong and New York, is using AI to develop a drug for an incurable lung disease, idiopathic pulmonary fibrosis.

CTOnews.com noted that the drug is currently in mid-term clinical trials in the United States and China, and preliminary results are expected in early 2025. The trial attracted a lot of attention in the pharmaceutical industry because Insilico not only used AI to identify a new way to fight the deadly disease, but also developed a new molecule to treat it. Deep Pharma Intelligence Research Institute in the UK pointed out that Insilico's drug is the first preclinical drug candidate found entirely by AI in the world.

Alex Zhavoronkov, founder and chief executive of Insilico, said Insilico was able to make a breakthrough because it "used AI to find a new target, found a molecule, and has entered a mid-term clinical trial." If the company's lung disease drugs are successfully developed, "that will change everything," he said. "

Welcome to subscribe "Shulou Technology Information " to get latest news, interesting things and hot topics in the IT industry, and controls the hottest and latest Internet news, technology news and IT industry trends.